Cargando…

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

INTRODUCTION: Sunitinib is the first-line targeted drug for the treatment of advanced renal cell carcinoma (RCC), but its therapeutic potential is limited by premature drug resistance. In an attempt to overcome this limitation, a sunitinib-resistant cell-derived xenograft (CDX) model of clear cell r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yingwei, Shangguan, Wentai, Chen, Zhiliang, Zheng, Zaosong, Chen, Yuqing, Zhong, Qiyu, Zhang, Yishan, Yang, Jingying, Zhu, Dingjun, Xie, Wenlian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687523/ https://www.ncbi.nlm.nih.gov/pubmed/34938069 http://dx.doi.org/10.2147/DDDT.S343718

Ejemplares similares

M2 macrophages secrete CXCL13 to promote renal cell carcinoma migration, invasion, and EMT
por: Xie, Yingwei, et al.
Publicado: (2021)

Circular RNA circPPP6R3 upregulates CD44 to promote the progression of clear cell renal cell carcinoma via sponging miR-1238-3p
por: Chen, Zhiliang, et al.
Publicado: (2021)

CircPVT1 promotes progression in clear cell renal cell carcinoma by sponging miR‐145‐5p and regulating TBX15 expression
por: Zheng, Zaosong, et al.
Publicado: (2021)

Conditional survival of trimodal therapy for nonmetastatic muscle‐invasive bladder cancer: A SEER database analysis
por: Shangguan, Wentai, et al.
Publicado: (2022)

Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database
por: Zhang, Yishan, et al.
Publicado: (2022)

Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Xie, Yingwei, et al.
Publicado: (2021)

CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma
por: Zheng, Zaosong, et al.
Publicado: (2019)

Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway
por: Li, Weicong, et al.
Publicado: (2018)

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
por: Diaz-Montero, C Marcela, et al.
Publicado: (2016)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer
por: Zhao, Fengjin, et al.
Publicado: (2014)

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
por: Small, Jeffrey, et al.
Publicado: (2017)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis
por: Butz, Henriett, et al.
Publicado: (2017)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Correction to: PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

Establishment of Drug Resistance in Human Gastric and Colon Carcinoma Xenograft Lines
por: Satta, Tetsuya, et al.
Publicado: (1991)

The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles()
por: Gaustad, Jon-Vidar, et al.
Publicado: (2017)

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2019)

Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells
por: Meng, Liang, et al.
Publicado: (2021)

Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
por: Kamli, Hossam, et al.
Publicado: (2018)

AB071. The role of long non-coding RNAs in sunitinib resistance of renal cancer
por: Qu, Le, et al.
Publicado: (2017)

Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma
por: Lu, Lu, et al.
Publicado: (2019)

QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis
por: Zhao, Tangliang, et al.
Publicado: (2021)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
por: Rausch, Magdalena, et al.
Publicado: (2021)

DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma
por: Zhao, Tangliang, et al.
Publicado: (2019)

Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
por: Lee, Alex Q., et al.
Publicado: (2021)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
por: Peng, Qiang, et al.
Publicado: (2019)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

LncRNA HOTAIR induces sunitinib resistance in renal cancer by acting as a competing endogenous RNA to regulate autophagy of renal cells
por: Li, Dechao, et al.
Publicado: (2020)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma
por: Pan, Yihui, et al.
Publicado: (2023)

Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2013)

Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nccq83ndr4pf4cuqvrk8bnqjr0